Xtandi-话题@MedSci

#Xtandi#

17篇内容 | 652人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653719, encodeId=1a891653e19ee, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准, objectType=article, longId=209089, objectId=845f2090899d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=845f2090899d, replyNumber=0, likeNumber=25, createdTime=2021-06-09, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=845f2090899d, moduleTitle=转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=845f2090899d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653718, encodeId=2af61653e18be, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=203137, objectId=f21a20313e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21a20313e8c, replyNumber=0, likeNumber=39, createdTime=2021-03-02, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21a20313e8c, moduleTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21a20313e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653717, encodeId=55ca1653e173a, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=前列腺癌治疗的ORIC-101联合XTANDI的Ib期临床试验正式开始, objectType=article, longId=186929, objectId=70311869299e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70311869299e, replyNumber=0, likeNumber=36, createdTime=2020-06-30, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70311869299e, moduleTitle=前列腺癌治疗的ORIC-101联合XTANDI的Ib期临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70311869299e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653715, encodeId=74c41653e15c2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=Xtandi成**获批FDA 前列腺癌口服疗法, objectType=article, longId=184883, objectId=a45f1848839f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a45f1848839f, replyNumber=0, likeNumber=28, createdTime=2020-06-29, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a45f1848839f, moduleTitle=Xtandi成**获批FDA 前列腺癌口服疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a45f1848839f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653716, encodeId=120a1653e1613, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌, objectType=article, longId=184900, objectId=b47618490022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b47618490022, replyNumber=0, likeNumber=30, createdTime=2020-05-21, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b47618490022, moduleTitle=恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b47618490022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653714, encodeId=5cc91653e148e, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查, objectType=article, longId=178215, objectId=9f1f1e821593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1f1e821593, replyNumber=0, likeNumber=28, createdTime=2019-10-08, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1f1e821593, moduleTitle=恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1f1e821593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果, objectType=article, longId=156671, objectId=78e61566e182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e61566e182, replyNumber=0, likeNumber=31, createdTime=2019-06-29, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e61566e182, moduleTitle=XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78e61566e182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653712, encodeId=281d1653e12b3, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌, objectType=article, longId=144569, objectId=4e5f14456932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5f14456932, replyNumber=0, likeNumber=35, createdTime=2018-12-17, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5f14456932, moduleTitle=FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5f14456932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=辉瑞/Astellas的Xtandi降低前列腺癌的扩散风险, objectType=article, longId=129145, objectId=e88a1291455c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e88a1291455c, replyNumber=0, likeNumber=27, createdTime=2018-05-26, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e88a1291455c, moduleTitle=辉瑞/Astellas的Xtandi降低前列腺癌的扩散风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e88a1291455c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653710, encodeId=a15e1653e10d8, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请, objectType=article, longId=64043, objectId=8f426404391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f426404391, replyNumber=0, likeNumber=24, createdTime=2016-07-14, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f426404391, moduleTitle=FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f426404391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653709, encodeId=f2b81653e09be, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=重磅！强生Zytiga霸主地位不保，安斯泰来前列腺癌药物Xtandi拿下欧美2大市场, objectType=article, longId=43576, objectId=d305435e687, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d305435e687, replyNumber=0, likeNumber=34, createdTime=2015-06-15, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d305435e687, moduleTitle=重磅！强生Zytiga霸主地位不保，安斯泰来前列腺癌药物Xtandi拿下欧美2大市场, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d305435e687)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653705, encodeId=f1531653e055b, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点, objectType=article, longId=25824, objectId=c92d2582476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c92d2582476, replyNumber=0, likeNumber=34, createdTime=2014-08-02, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c92d2582476, moduleTitle=安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c92d2582476)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653704, encodeId=cf1f1653e0446, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=英国NICE推荐安斯泰来前列腺癌药物Xtandi用于国家卫生系统, objectType=article, longId=25579, objectId=a864255e9c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a864255e9c2, replyNumber=0, likeNumber=33, createdTime=2014-05-24, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a864255e9c2, moduleTitle=英国NICE推荐安斯泰来前列腺癌药物Xtandi用于国家卫生系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a864255e9c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653708, encodeId=e80c1653e0862, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=安斯泰来和Medivation向FDA提交前列腺癌药物Xtandi sNDA, objectType=article, longId=32113, objectId=e95932113e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95932113e6, replyNumber=0, likeNumber=25, createdTime=2015-01-28, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95932113e6, moduleTitle=安斯泰来和Medivation向FDA提交前列腺癌药物Xtandi sNDA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e95932113e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653707, encodeId=85511653e07c3, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=安斯泰来和Medivation启动Xtandi III期PROSPER试验, objectType=article, longId=27671, objectId=50962e6713b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50962e6713b, replyNumber=0, likeNumber=28, createdTime=2014-03-14, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50962e6713b, moduleTitle=安斯泰来和Medivation启动Xtandi III期PROSPER试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50962e6713b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653706, encodeId=5b131653e06de, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=安斯泰来与Medivation启动前列腺癌新药Xtandi IV期研究, objectType=article, longId=26618, objectId=c1e3266180b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e3266180b, replyNumber=0, likeNumber=25, createdTime=2014-07-21, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e3266180b, moduleTitle=安斯泰来与Medivation启动前列腺癌新药Xtandi IV期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e3266180b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653703, encodeId=7ff31653e03a0, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, objectTitle=FDA批准治疗晚期前列腺癌新药Xtandi, objectType=article, longId=9511, objectId=f334951169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f334951169, replyNumber=0, likeNumber=33, createdTime=2013-04-20, rootId=0, userName=lingaifan, userId=f30024340037, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f334951169, moduleTitle=FDA批准治疗晚期前列腺癌新药Xtandi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f334951169)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Xtandi

2020-05-29

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准

2021-06-09

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌

2021-03-02

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

前列腺癌治疗的ORIC-101联合XTANDI的Ib期临床试验正式开始

2020-06-30

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

Xtandi成**获批FDA 前列腺癌口服疗法

2020-06-29

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌

2020-05-21

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

恩杂鲁胺XTANDI治疗转移性前列腺癌获得FDA的优先审查

2019-10-08

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果

2019-06-29

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

FDA扩大了辉瑞/安斯泰来的Xtandi的适应症用以治疗非转移性前列腺癌

2018-12-17

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

辉瑞/Astellas的Xtandi降低前列腺癌的扩散风险

2018-05-26

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

FDA受理安斯泰来新一代前列腺癌口服药物Xtandi补充新药申请

2016-07-14

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

重磅！强生Zytiga霸主地位不保，安斯泰来前列腺癌药物Xtandi拿下欧美2大市场

2015-06-15

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

安斯泰来前列腺癌新药Xtandi III期PREVAIL达主要终点

2014-08-02

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

英国NICE推荐安斯泰来前列腺癌药物Xtandi用于国家卫生系统

2014-05-24

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

安斯泰来和Medivation向FDA提交前列腺癌药物Xtandi sNDA

2015-01-28

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

安斯泰来和Medivation启动Xtandi III期PROSPER试验

2014-03-14

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

安斯泰来与Medivation启动前列腺癌新药Xtandi IV期研究

2014-07-21

lingaifan (审核中...)

前往app查看评论内容

#Xtandi#

FDA批准治疗晚期前列腺癌新药Xtandi

2013-04-20

科室
- - 订阅+
  - 更多科室
工具
服务